Astrana Health, Inc. (NASDAQ:ASTH) Short Interest Update

Astrana Health, Inc. (NASDAQ:ASTH) saw a large drop in short interest in February. As of February 28th, there was short interest totalling 1,440,000 shares, a drop of 23.0% from the February 13th total of 1,870,000 shares. Based on an average daily trading volume, of 346,500 shares, the days-to-cover ratio is currently 4.2 days. Approximately 3.9% of the company’s shares are sold short.

Astrana Health Stock Performance

NASDAQ:ASTH opened at $32.03 on Wednesday. The company’s 50-day moving average price is $33.97 and its 200-day moving average price is $42.83. The company has a current ratio of 1.91, a quick ratio of 1.91 and a debt-to-equity ratio of 0.60. The company has a market cap of $1.80 billion, a P/E ratio of 24.64, a P/E/G ratio of 1.37 and a beta of 1.30. Astrana Health has a twelve month low of $23.12 and a twelve month high of $63.20.

Astrana Health (NASDAQ:ASTH) last released its quarterly earnings data on Thursday, February 27th. The company reported ($0.15) earnings per share (EPS) for the quarter, missing the consensus estimate of $0.22 by ($0.37). Astrana Health had a return on equity of 9.37% and a net margin of 3.63%. The firm had revenue of $665.21 million for the quarter, compared to analyst estimates of $617.24 million. On average, sell-side analysts forecast that Astrana Health will post 1.15 earnings per share for the current fiscal year.

Analyst Ratings Changes

Several research firms have recently commented on ASTH. Macquarie upgraded shares of Astrana Health to a “hold” rating in a report on Monday, December 16th. Stifel Nicolaus reduced their price target on shares of Astrana Health from $70.00 to $56.00 and set a “buy” rating for the company in a report on Thursday, February 20th. Bank of America reduced their price target on shares of Astrana Health from $55.00 to $49.00 and set a “buy” rating for the company in a report on Tuesday, March 4th. Robert W. Baird reduced their price target on shares of Astrana Health from $86.00 to $50.00 and set an “outperform” rating for the company in a report on Monday, March 3rd. Finally, Truist Financial cut their price objective on shares of Astrana Health from $50.00 to $46.00 and set a “buy” rating on the stock in a research report on Tuesday. Two equities research analysts have rated the stock with a hold rating, six have given a buy rating and one has given a strong buy rating to the stock. According to data from MarketBeat.com, the company has a consensus rating of “Moderate Buy” and an average target price of $56.17.

Institutional Investors Weigh In On Astrana Health

Several hedge funds and other institutional investors have recently bought and sold shares of the company. Janus Henderson Group PLC acquired a new stake in shares of Astrana Health during the third quarter valued at about $1,164,000. Royce & Associates LP acquired a new stake in shares of Astrana Health during the third quarter valued at about $6,661,000. Principal Financial Group Inc. purchased a new position in shares of Astrana Health in the third quarter valued at approximately $13,383,000. Loomis Sayles & Co. L P purchased a new position in shares of Astrana Health in the third quarter valued at approximately $30,251,000. Finally, Victory Capital Management Inc. purchased a new position in shares of Astrana Health in the third quarter valued at approximately $2,596,000. 52.77% of the stock is currently owned by institutional investors and hedge funds.

Astrana Health Company Profile

Astrana Health, Inc, Inc, a physician-centric technology-powered healthcare management company, provides medical care services in the United States. It operates through three segments: Care Partners, Care Delivery, and Care Enablement. The company is leveraging its proprietary population health management and healthcare delivery platform, operates an integrated, value-based healthcare model which empowers the providers in its network to deliver care to its patients.